TOT BIOPHARM International (HKG:1875) reported a net profit attributable to the equity holders of 35.4 million yuan for the nine months ended Sept. 30, compared with a loss of 32.4 million yuan in the corresponding period of the previous year, according to a Tuesday filing with the Hong Kong Stock Exchange.
The company's revenue was 809.0 million yuan, compared with 542.0 million yuan in the previous year period.
The company's shares were down about 6% in the recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.